NEWS
Peptide therapy news
Regulatory moves, FDA actions, new research and what the industry does about it. The reporting lives on our editorial hub, PeptideWellness — every headline below opens there.
STUDY
Retatrutide beat Ozempic 2 mg in its first head-to-head trial
November 4, 2026 / 3 min read · on PeptideWellness ↗
INDUSTRY
LegitScript will now certify sellers of six compounded peptides
November 2, 2026 / 2 min read · on PeptideWellness ↗
DECISION
HHS lets pharmacies compound six peptides, with conditions
October 28, 2026 / 6 min read · on PeptideWellness ↗
SAFETY
Two compounders recall GLP-1 injections over sterility
October 21, 2026 / 3 min read · on PeptideWellness ↗
INDUSTRY
GLP-1 prices barely moved in 2026. Here is the data
September 11, 2026 / 6 min read · on PeptideWellness ↗
INDUSTRY
GLP-1 muscle loss: what Nestle's new push reveals
August 18, 2026 / 7 min read · on PeptideWellness ↗
ENFORCEMENT
FDA warning letters now reach research-peptide sellers
July 28, 2026 / 8 min read · on PeptideWellness ↗
DECISION
FDA advisory panel overruled its reviewers on six of seven
July 27, 2026 / 8 min read · on PeptideWellness ↗
PROPOSAL
FDA reviewers say no: seven peptides face 503A advisory vote
July 22, 2026 / 6 min read · on PeptideWellness ↗
ENFORCEMENT
FDA cited 25 telehealth GLP-1 sellers in one wave
June 18, 2026 / 6 min read · on PeptideWellness ↗